Publications by authors named "Mukul Sehrawat"

Article Synopsis
  • A study in India assessed the effectiveness, cost-effectiveness, and quality of life (QoL) for patients with multiple sclerosis (MS) undergoing treatment with disease-modifying drugs (DMTs), analyzing data from 74 participants.
  • The findings indicated that natalizumab led to the greatest reduction in annualized relapse rate (ARR), while teriflunomide excelled in improving QoL and was the most affordable option.
  • Overall, while natalizumab was effective in reducing relapses, teriflunomide provided a balance of effectiveness and affordability, making it a suitable choice for patients from various socio-economic backgrounds.
View Article and Find Full Text PDF